(0.32%) 5 116.46 points
(0.32%) 38 361 points
(0.35%) 15 984 points
(-0.85%) $83.14
(5.93%) $2.04
(0.37%) $2 355.90
(0.47%) $27.67
(4.00%) $959.00
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
4 days till quarter result
(bmo 2024-05-03)
Expected move: +/- 9.69%
@ $25.17
発行日: 14 2月 2024 @ 23:30
リターン: -16.34%
前回のシグナル: 2月 13 - 23:31
前回のシグナル:
リターン: -0.59 %
Live Chart Being Loaded With Signals
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally...
Stats | |
---|---|
本日の出来高 | 65 452.00 |
平均出来高 | 215 987 |
時価総額 | 627.15M |
EPS | $0 ( 2024-02-28 ) |
次の収益日 | ( $-0.330 ) 2024-05-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.74 |
ATR14 | $0.0390 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Hsieh Ming | Buy | 1 000 000 | Forward sale contract (obligation to sell) |
2024-03-08 | Hsieh Ming | Sell | 1 000 000 | Forward sale contract (obligation to sell) |
2024-03-01 | Xie Jian | Sell | 1 075 | Common Stock |
2024-03-01 | Xie Jian | Sell | 404 | Common Stock |
2024-03-01 | Kim Paul | Sell | 1 129 | Common Stock |
INSIDER POWER |
---|
2.45 |
Last 99 transactions |
Buy: 2 068 563 | Sell: 1 956 842 |
ボリューム 相関
Fulgent Genetics Inc 相関 - 通貨/商品
Fulgent Genetics Inc 財務諸表
Annual | 2023 |
収益: | $289.21M |
総利益: | $96.61M (33.40 %) |
EPS: | $-5.63 |
FY | 2023 |
収益: | $289.21M |
総利益: | $96.61M (33.40 %) |
EPS: | $-5.63 |
FY | 2022 |
収益: | $618.97M |
総利益: | $366.90M (59.28 %) |
EPS: | $4.76 |
FY | 2021 |
収益: | $992.58M |
総利益: | $777.05M (78.29 %) |
EPS: | $17.25 |
Financial Reports:
No articles found.
Fulgent Genetics Inc
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。